Metinvest, the vertically integrated steel and mining group of companies, has signed its first smart contract on we.trade blockchain trade finance platform supported by UniCredit.
According to a press release provided by Metinvest Group, this blockchain transaction demonstrates the importance of digitalization in the steel industry.
“Importantly, this is the first blockchain transaction provided by UniCredit to Metinvest Group and is a new digital instrument for us. Blockchain technology allows for the creation and management of a large distributed transaction management database that can be shared across multiple nodes of a network. Such transactions demonstrate the Group’s willingness to work in a trusted environment with secure technology, improved risk mitigation and enhanced visibility,” a press service quotes Head of Corporate Finance at the European Re-rolling Business Unit of Metinvest Group, Jamilya Baimukhambetova, as saying.
According to the press release, the underlying transaction is the purchase of equipment for one of Metinvest’s production re-rollers from a European supplier. One of the pilot project’s objectives is to try the new platform from the client side, so that the Group can evaluate its potential as a new type of payment terms that it can offer to some of its major customers.
Exploring the potential of blockchain trade finance is one way that Metinvest Group is implementing its digital innovation strategy, the Group said in its press release.
The we.trade platform works in partnership with major European banks (Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Italy, Netherlands, Norway, Spain, Sweden and Switzerland) and is based on distributed ledger technology, the major underlying elements of which include blockchain and smart contracts. When a smart contract is created on the we.trade platform, the payment will be automatically triggered according to the terms agreed by the counterparties once the buyer has confirmed the delivery of the goods, making the transaction considerably faster and more transparent.
According to the press release, we.trade is a truly successful inter-bank collaboration that can help to redefine business relationships among companies, removing obstacles that typically make international transactions costly and complex while delivering benefits for corporates.
Metinvest Group is a vertically integrated group of steel and mining companies that manages every link of the value chain, from mining and processing iron ore and coal to making and selling semi-finished and finished steel products. It comprises steel and mining production facilities located in Ukraine, Europe and the US, as well as a sales network covering all key global markets. Metinvests business is divided for financial reporting purposes into two segments: metallurgical and mining. The Group ended the first quarter with revenues of $2.9 billion and an EBITDA margin was 15%.
Metinvest Holding LLC is the management company of Metinvest Group.
The share of public procurement of medicines in January-March 2019 totaled 20% of the Ukrainian pharmaceutical market, SMD consulting company (Kyiv) has said after studying the Ukrainian pharmaceutical market.
According to the company, in January-March 2019, budget medical procurement in monetary terms increased 40% compared to the same period of 2018 in the centralized procurement segment and by 19% in the procurement segment of medical institutions.
In addition, budget procurement in kind increased 134% in the segment of centralized procurement and by 13% in procurement by hospitals.
At the same time, the company said that in the first quarter of 2019, hospitals, in accordance with their needs, used the ending stocks of the 2018 budget funds to purchase drugs and expensive medicines.
In general, in the first quarter of 2019, the pharmaceutical market of Ukraine grew by 11% in monetary terms compared to the same period of 2018, to UAH 13 billion, while in kind it fell by 7%, to 177 million packages.
At the same time, according to the analysts of the company, the prescription segment in the first quarter of 2019 grew by 17% in monetary terms and decreased 1% in physical terms.
In addition, in the first quarter of 2019, sales of foreign manufacturers in kind decreased 5%, while sales of Ukrainian pharmaceutical manufacturers decreased 8%.
